Lipid and protein oxidation in female patients with chronic fatigue syndrome

Archives of Medical Science

Volumn 8, Issue 5, 2012, Pages 886-891

  Tomic, Slavica ^a   Brkic, Snezana ^a   Maric, Daniela ^a   Mikic, Aleksandra Novakov ^a  

^a CLINICAL CENTER OF VOJVODINA   (Serbia)

Author keywords

Atherosclerosis; Chronic fatigue syndrome; Malondialdehyde; Oxidative stress; Protein carbonyl

Indexed keywords

ANTIOXIDANT; CARBONYL DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PROTEIN CARBONYL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; LIPID OXIDATION; OXIDATIVE STRESS; PROTEIN METABOLISM; PROTEIN OXIDATION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84869853604     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.31620     Document Type: Article

References (51)

1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387-9.
2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-9. (Pubitemid 24370860)
3. Griffith JP, Zarrouf FA. A systematic review of chronic fatigue syndrome: don't assume it's depression. Prim Care Companion J Clin Psychiatry 2008; 10: 120-8. (Pubitemid 351872800)
4. Centers for Disease Control and Prevention. Chronic Fatigue Syndrome. May 26, 2006. Available at: www.cdc.gov/cfs. Accessed March 21, 2010.
5. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006; 37: 139-50. (Pubitemid 44548485)
6. Jason LA, Taylor RR, Kennedy CL, et al. Chronic fatigue syndrome: Sociodemographic subtypes in a community-based sample. Evaluation and the Health Professions 2000; 23: 243-63. (Pubitemid 30655957)
7. Torres-Harding SR, Jason LA, Taylor RR. Fatigue severity, attributions, medical utilization, and symptoms in persons with chronic fatigue. J Behav Med 2002; 25: 99-113. (Pubitemid 37490054)
8. Griffith JP, Jason LA, Porter N, et al. CFS: a review of epidemiology and natural history studies. Bulletin of the IACFS/ME 2009; 17: 96-8.
9. Fernández AA, Martín AP, Martínez MI, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry 2009; 9 (Suppl 1): S1.
10. Cope H, Mann A, Pelosi A, David A. Psychosocial risk factors for chronic fatigue and chronic fatigue syndrome following presumed viral illness: a case-control study. Psychol Med 1996; 26: 1197-209. (Pubitemid 26382014)
11. Dalpke AH, Reiner T, Ritter K. Oxidative injury to endothelial cells to Epstein-Barr virus-induced autoantibodies against superoxide dismutase. J Med Virol 2003; 71: 408-16. (Pubitemid 37176631)
12. Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ. Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology 2007; 55: 112-20. (Pubitemid 47077212)
13. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocrine Rev 2003; 24: 236-52. (Pubitemid 36515286)
14. Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 2000; 5: 35-41. (Pubitemid 30389534)
15. Jammes Y, Steinberg JG, Mamabrini O, Bregeon F, Delliaux S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005; 257: 299-310. (Pubitemid 40342133)
16. Pall ML, Scatterle JD. Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder. Ann N Y Acad Sci 2001; 933: 323-9. (Pubitemid 32386045)
17. Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001; 6: 450-9. (Pubitemid 33041792)
18. Vecchiet J, Cipollone F, Falasca K, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 2003; 335: 151-4. (Pubitemid 36071622)
19. Kennedy G, Spence, VA, McLaren M, Hill A, Underwood C, Belch J. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Rad Bio Med 2005; 39: 584-9. (Pubitemid 41112100)
20. Fulle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000; 29: 1252-9.
21. Keenoy MY, Moorkens G, Vertommen J, De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001; 68: 2037-49. (Pubitemid 32245604)
22. Del Rio D, Stewart A, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005; 15: 316-28. (Pubitemid 41190990)
23. Polidori MC, Savino K, Alunni G, et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med 2002; 32: 148-52. (Pubitemid 34127704)
24. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003; 34: 1-10. (Pubitemid 36043881)
25. Delibas N, Ozcankaya R, Altuntas I. Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 2002; 35: 137-41. (Pubitemid 34442693)
26. VanderVeen LA, Hashim MF, Shyr Y, Marnett LJ. Induction of frame shift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde. Proc Natl Acad Sci U S A 2003; 100: 14247-52. (Pubitemid 37499222)
27. Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, Marnett LJ. Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 2003; 278: 31426-33. (Pubitemid 36994664)
28. Sakuma S, Sumi H, Kohda T, Arakawa Y, Fujimoto Y. Effects of lipid peroxidation-derived products on the growth of human colorectal cancer cell line HT-29. J Clin Biochem Nutr 2009; 45: 171-7.
29. Catalá A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids 2009; 157: 1-11.
30. Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 2003; 248: 93-5. (Pubitemid 36833645)
31. Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002; 32: 797-803. (Pubitemid 34439250)
32. Dalle-Donne I, Rossi R, Giustarini D, Milzania A, Colombo R. Protein carbonyl groups as biomarkers of oxi dative stress. Clinica Chimica Acta 2003; 329: 23-38. (Pubitemid 36187411)
33. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-76. (Pubitemid 36626706)
34. Aaronson LS, Teel SC, Cassmeyer V, et al. Definiting and measuring fatigue J Nursing Scholarhip 1999; 31: 1.
35. Zachisson O, Regland B, Jahreskog M, Kron M, Gotfries C. A rating scale for fibromyalgia and chronic fatigue syndrome (the Fibro Fatigue Scale). J Psychosom Res 2002; 52: 501-9. (Pubitemid 34759879)
36. Garcia-Campayo J, Pascual A, Aida M, Marzo J, Magallon R, Fortes S. The Spanish version of the Fibro Fatigue Scale:validation of a questionnaire for the observers assessment of fibromyalgia and chronic fatigue syndrom. Gen Hosp Psych 2006; 28: 154-60. (Pubitemid 43324678)
37. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 2000; 28: 1685-96. (Pubitemid 30628655)
38. Tamer L, Sucu N, Polat G, et al. Decreased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serummalon dialdehyde in atherosclerotic patients. Arch Med Res 2002; 33: 257-60. (Pubitemid 34553351)
39. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-83. (Pubitemid 29411736)
40. Boaz M, Matas Z, Biro A, et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438-44. (Pubitemid 29413615)
41. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000; 33: S99-108.
42. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000; 32: 307-26. (Pubitemid 32001909)
43. Dodani S, Marion L, Sharma G, Reed GL, George V. The association of carotid intima media thickness with dysfunctional HDL in South Asians. Arch Med Sci 2008; 4: 40-6. (Pubitemid 351588820)
44. Vulic D, Loncar S, Krneta M, et al. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci 2010; 6: 270-5.
45. Mark L, Paragh G, Karadi I, Reiber I, Pados G. Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. Arch Med Sci 2010; 6: 695-700.
46. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 2005; 16: 442-6. (Pubitemid 41017628)
47. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72. (Pubitemid 39390578)
48. Kȩdziora-Kornatowska K, Czuczejko J, Motyl J, et al. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. Arch Med Sci 2010; 6: 513-8.
49. Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem 2010; 21: 267-71.
50. Kostulski A, Pawełczyk T, Rabe-Jabłoñska J. The risk of significant body weight gain and abdominal obesity during short-term treatment with olanzapine Arch Med Sci 2009; 5: 259-66.
51. Spence VA, Kennedy G, Belch JJF, Hill A, Khan F. Low-grade inflammation and arterial wave reflection in patients with chronic fatigue syndrome. Clin Sci 2008; 114: 561-6. (Pubitemid 351548764)